A steady stream of structural trial data, approvals, reimbursement decisions, and real-world rollouts arrived in 2025.
WAYNE, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX), a leading global provider of medical technologies, today announced the first patient enrollment in a clinical registry that ...
Atlanta — A randomized transcatheter aortic valve replacement (TAVR) trial demonstrated that a self-expanding device performs better on multiple prognostically important measures of valve function at ...
GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced initial positive results from its U.S. IDE ...
WASHINGTON — A phase 3 randomized trial will soon begin for the first transcatheter aortic valve replacement (TAVR) device for the treatment of aortic valve regurgitation after promising results in a ...
A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...
A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback